Rapport Therapeutics (RAPP) Corporate presentation summary

Leadership and expertise

• Executive team and board have extensive experience in neuroscience, biotech, and pharma, with backgrounds at major companies and successful track records in drug development.

Precision neuroscience platform and pipeline

• Focus on small molecule precision medicines for neurological and psychiatric disorders, leveraging receptor associated proteins (RAPs) for high selectivity and specificity.

• Lead program RAP-219 targets TARPγ8, a protein selectively expressed in brain regions implicated in focal onset seizures.

• Pipeline includes programs for focal onset seizures, primary generalized tonic-clonic seizures, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

RAP-219 clinical development and results

• Phase 2a trial in drug-resistant focal onset seizures showed 71% median reduction in long episodes and 77.8% reduction in clinical seizures, with 24% achieving seizure freedom at 8 weeks.

• RAP-219 was generally well tolerated, with most adverse events mild or moderate and a 10% discontinuation rate.

• Phase 3 program initiated in Q2 2026, with two global, placebo-controlled trials underway.